S. 272: Protect Infant Formula from Contamination Act
Sponsor
Gary Peters
Democrat · MI
Bill Progress
Latest Action · Jan 28, 2026
Placed on Senate floor schedule under General Orders. Calendar No. 306.
Flag tainted baby formula before it ships, not after
Why it matters
Today, a confirmed contamination test inside a formula plant doesn't have to reach the FDA until the product has already left the building. S. 272 closes that gap: a positive hit for salmonella or another dangerous microbe would have to be reported within one business day, even if the cans are still sitting in the warehouse. The bill also locks in quarterly supply reports for 5 years so empty shelves get spotted early.
S. 272 tightens the rules for what happens the moment infant formula looks unsafe. Right now, a maker generally only has to alert the FDA about contaminated or mislabeled formula once it has already left the company's control. This bill pulls that trigger earlier: a confirmed positive test for a microbe like salmonella in a finished batch would have to be reported within one business day, even if every can is still in the warehouse.
The FDA would be on the same short clock. Within one business day of getting that notice, the agency would have to respond and start working through the investigation and any corrective action. Within 90 days, it would have to confirm — backed by the company's own documentation — that a proper investigation is actually happening, right down to whether the lab's testing method or sample handling could have skewed the result.
The maker doesn't just file a notice and move on. It would have to consult with the FDA about isolating the affected product, stop distribution if the agency requires it, and hand over the lab results and genetic sequencing from the positive sample.
The bill also looks past any single recall. It requires a progress report within 180 days on the FDA's January 2025 strategy for a more resilient formula market, then supply-chain reports — including in-stock rates — at least every quarter for 5 years. Deeper reviews at the 1-, 3-, and 5-year marks would dig into which manufacturing practices actually improve both safety and supply.
S. 272 Bill Summary
What S. 272 actually does.
Companies must report contamination within 1 business day
If a formula maker learns a product may be adulterated or mislabeled, it must notify the Secretary within 1 business day instead of reporting on an open-ended timeline.
Contamination must be reported before formula ships, not just after
Today a maker generally must alert the FDA only once contaminated formula has left its control. This bill requires a confirmed positive microbe test in a finished batch to be reported within 1 business day, whether or not the product has shipped.
FDA has 1 business day to respond
After receiving a notice, the Secretary must respond within 1 business day to begin discussions about the investigation and corrective action.
Manufacturers may have to stop distribution
After a confirmed positive result, a company must consult with the Secretary about isolating the affected product and, if required, stop distribution and properly dispose of it.
FDA gets 90 days to verify the investigation
Within 90 days of a contamination notice, the Secretary must confirm through documentation that the manufacturer performed, or is performing, an appropriate investigation and corrective action.
Formula supply gets quarterly oversight for 5 years
The bill requires a progress report within 180 days, supply-chain reports starting within 270 days and continuing at least quarterly for 5 years, plus broader supply-adequacy reviews at 1 year, 3 years, and 5 years.
Who benefits from S. 272?
Parents feeding babies formula
You would get a faster response system when contamination is suspected, with both manufacturers and FDA operating on a 1-business-day deadline.
Infants who rely on formula
The bill is designed to shorten the time between a confirmed contamination problem and the actions needed to isolate product, stop distribution, and review what went wrong.
Families hit by formula shortages
You could benefit from longer-term oversight of supply, since the bill requires quarterly reports for 5 years and additional reviews on whether formula availability is actually adequate.
Congress overseeing formula safety
Lawmakers would get recurring reports on in-stock rates, supply conditions, and the FDA's progress carrying out its market resiliency strategy.
Who is affected by S. 272?
Infant formula manufacturers
They would face faster reporting deadlines, more documentation demands, and potential orders to isolate, stop distributing, or dispose of affected formula.
FDA and HHS officials
They would have new response deadlines: 1 business day to engage after a contamination notice, 90 days to confirm the company's investigation, and multiple reporting obligations over 5 years.
Testing labs and quality-control teams
Their testing methods and handling practices could receive closer review, because the bill tells the Secretary to consider laboratory methods and possible cross-contamination during testing.
USDA and other federal agencies
They would be pulled into ongoing coordination about immediate formula needs and long-term market resiliency.
S272 Legislative Journey
Committee Action
Jan 28, 2026
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute and an amendment to the title. Without written report.
Passed Committee
Jan 15, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Committee Action
Jan 28, 2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
About the Sponsor
Gary Peters
Democrat, MI · 17 years in Congress
Committees: Homeland Security and Governmental Affairs, Commerce, Science, and Transportation, Armed Services
View full profile →
Cosponsors (9)
This bill has 9 cosponsors: 6 Democrats, 3 Republicans, reflecting bipartisan support. Cosponsors represent 8 states: Maine, Minnesota, North Dakota, and 5 more.
Committee Sponsors
Health, Education, Labor, and Pensions Committee
5 of 23 committee members cosponsored
6 Democrats across this committee haven't cosponsored yet. Mobilize their constituents
S. 272 Quick Facts
- Committee
- Health, Education, Labor, and Pensions
- Chamber
- Senate
- Policy
- Health
- Introduced
- Jan 28, 2025
Placed on Senate floor schedule under General Orders. Calendar No. 306.
Jan 28, 2026
Official Sources
Official bill page with status, text, sponsors, and legislative actions for the Protect Infant Formula from Contamination Act.
The bill's 1-business-day reporting trigger keys off a confirmed positive result for a microorganism this regulation already requires finished infant formula to be tested for.
S. 272 amends section 412 of the Federal Food, Drug, and Cosmetic Act, codified here, which governs infant formula safety and reporting.
The bill's 180-day progress report tracks the FDA's January 2025 resiliency strategy named in this document.
FDA's central hub for infant formula safety, recalls, and supply, the regulatory backdrop the bill builds on.
Guidance for the manufacturers who would face the bill's faster reporting deadlines and corrective-action requirements.
Explains how FDA communicates and acts on food safety problems, relevant when contaminated formula must be isolated or pulled from distribution.
S. 272 Common Questions
How fast would formula companies have to report contamination under S. 272?
Within 1 business day. If a manufacturer learns a formula may be contaminated or mislabeled, S. 272 says it must notify the government on that timeline.
What does S. 272 change about current law?
Right now, a maker generally has to alert the FDA about contaminated formula only once it has left the company's control. S. 272 requires a confirmed positive test in a finished batch to be reported within 1 business day, even if the cans are still in the warehouse.
What kind of contamination triggers the 1-day report?
A confirmed positive test in a finished batch for a microbe the formula is already required to be tested for, such as salmonella. The maker also has to hand over the lab results and genetic sequencing from the positive sample.
How quickly would FDA have to respond to a formula contamination report?
Also within 1 business day. S. 272 requires the Secretary to respond and begin discussions about the investigation and corrective action right away.
Could the government make a company stop selling affected formula?
Yes. After a confirmed positive result, the manufacturer must consult with the Secretary and may be required to isolate the product, stop distribution, and dispose of it.
How long would FDA have to verify the company's investigation?
90 days. The bill says the Secretary must confirm through documentation that the manufacturer performed, or is performing, an appropriate investigation and corrective action.
Does S. 272 do anything about formula shortages?
Yes. It requires a progress report within 180 days, then supply-chain reports starting within 270 days and continuing at least quarterly for 5 years.
Is S. 272 bipartisan, and where does it stand?
It's bipartisan. Democrat Gary Peters leads it with nine cosponsors from both parties, including Republicans John Hoeven, Susan Collins, and Deb Fischer. It cleared the Senate HELP Committee and sits on the Senate calendar, awaiting floor time.
Based on S. 272 bill text
S. 272 Bill Text
“To improve the safety of infant formula through testing of infant formula for microorganisms and toxic elements, and for other purposes.”
Source: U.S. Government Publishing Office
Get notified when S. 272 moves
Committee votes, floor action, cosponsor changes — straight to your inbox.
Bill alerts + Legisletter's monthly briefing. Unsubscribe anytime.
Health Bills
9 related bills we're tracking
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.
Oct 3, 2025
Mikaela Naylon Give Kids a Chance Act
Received in the Senate.
Dec 2, 2025
Improving Seniors’ Timely Access to Care Act of 2025
Forwarded by Subcommittee to Full Committee by Voice Vote.
Jun 25, 2026
CONNECT for Health Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 26, 2025
Momnibus Act
Referred to the Subcommittee on Health.
Apr 20, 2026
Right to Contraception Act
Referred to the House Committee on Energy and Commerce.
Feb 5, 2025
Women’s Health Protection Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 24, 2025
Medicare Patient Access and Practice Stabilization Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 31, 2025
EACH Act of 2025
Referred to the Subcommittee on Health.
Dec 19, 2025
Trending Right Now
Bills gaining momentum across Congress
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Placed on the Union Calendar, Calendar No. 628.
Jul 2, 2026
More Homes on the Market Act
Referred to the House Committee on Ways and Means.
Feb 13, 2025
Ensuring Community Access to Pharmacist Services Act
Ordered to be Reported in the Nature of a Substitute by Voice Vote.
May 21, 2026
Tracking Health in Congress? Monitor bills, track cosponsor momentum, and launch advocacy campaigns — all from one advocacy platform.